NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT05874414 2026-01-22Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaGenfitPhase 1/2 Recruiting74 enrolled